ORPEA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.32 EUR | +4.06% |
|
+5.30% | -21.18% |
| Apr. 30 | Emeis: sale of a real estate portfolio in the Netherlands | CF |
| Apr. 30 | Orpea's Emeis Sells Dutch Nursing Home Portfolio in EUR97 Million Deal | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company appears to be poorly valued given its net asset value.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Most analysts recommend that the stock should be sold or reduced.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -22.47% | 2.18B | B- | ||
| -0.43% | 1.42B | - | C+ | |
| -28.49% | 1.35B | - | ||
| +20.45% | 1.35B | B | ||
| +17.49% | 716M | - | B | |
| -1.82% | 457M | B- | ||
| +234.37% | 424M | - | D+ | |
| -8.27% | 320M | - | - | |
| +3.37% | 130M | B |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ORP Stock
- Ratings ORPEA
